These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11531415)

  • 1. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7.
    Aarons EJ; Beddows S; Willingham T; Wu L; Koup RA
    Virology; 2001 Sep; 287(2):382-90. PubMed ID: 11531415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
    Khurana S; Kennedy M; King LR; Golding H
    J Virol; 2005 Jun; 79(11):6791-800. PubMed ID: 15890918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection.
    Zhang L; Huang Y; Yuan H; Tuttleton S; Ho DD
    Virology; 1997 Feb; 228(2):340-9. PubMed ID: 9123841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
    Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and biological interactions between two HIV-1 strains from a coinfected patient reveal the first evidence in favor of viral synergism.
    Wang B; Lal RB; Dwyer DE; Miranda-Saksena M; Boadle R; Cunningham AL; Saksena NK
    Virology; 2000 Aug; 274(1):105-19. PubMed ID: 10936093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.
    Pacchia AL; Adelson ME; Kaul M; Ron Y; Dougherty JP
    Virology; 2001 Mar; 282(1):77-86. PubMed ID: 11259192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of the env gene of two CCR5/CXCR4-independent human immunodeficiency 2 primary isolates.
    Santos-Costa Q; Parreira R; Moniz-Pereira J; Azevedo-Pereira JM
    J Med Virol; 2009 Nov; 81(11):1869-81. PubMed ID: 19774680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
    Burke B; Derby NR; Kraft Z; Saunders CJ; Dai C; Llewellyn N; Zharkikh I; Vojtech L; Zhu T; Srivastava IK; Barnett SW; Stamatatos L
    Virology; 2006 Nov; 355(2):138-51. PubMed ID: 16920175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1.
    Siciliano SJ; Kuhmann SE; Weng Y; Madani N; Springer MS; Lineberger JE; Danzeisen R; Miller MD; Kavanaugh MP; DeMartino JA; Kabat D
    J Biol Chem; 1999 Jan; 274(4):1905-13. PubMed ID: 9890944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine.
    Misumi S; Nakajima R; Takamune N; Shoji S
    J Virol; 2001 Dec; 75(23):11614-20. PubMed ID: 11689643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Functional roles of HIV-1 accessory genes for its pathogenicity].
    Adachi A; Kamada K; Hatcho K; Yamashita T; Uchiyama T; Nomaguchi M
    Tanpakushitsu Kakusan Koso; 2007 Aug; 52(10 Suppl):1261-7. PubMed ID: 17824250
    [No Abstract]   [Full Text] [Related]  

  • 15. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.
    Lee B; Sharron M; Blanpain C; Doranz BJ; Vakili J; Setoh P; Berg E; Liu G; Guy HR; Durell SR; Parmentier M; Chang CN; Price K; Tsang M; Doms RW
    J Biol Chem; 1999 Apr; 274(14):9617-26. PubMed ID: 10092648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
    Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
    Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.